San Antonio, Texas USA (UroToday.com) Behfar Ehdaie, Memorial Sloan Kettering Cancer Center, reviewed issues regarding discussions with patients regarding outcomes with partial gland ablation.
Biopsy pathology is associated with recurrent disease. Focal ablation is not cure and needs to be carefully discussed with patients. Retreatment is not uncommon after partial gland ablation in addition to possibly increased costs associated with these treatments versus more definitive measures. Partial gland ablation is safe and has favorable functional outcomes, however, continence and potency may not be the only meaningful quality of life endpoints. Patient orgasm, ejaculatory dysfunction and painful intercourse in addition to other factors within urinary sexual domains measured with standardized instruments need to be taken into careful consideration.
Presented by: Behfar Ehdaie, Memorial Sloan Kettering Cancer Center
Written By: Stephen B. Williams, MD and Ashish M. Kamat
17th Annual Meeting of the Society of Urologic Oncology - November 30 -December 2, 2016 – San Antonio, Texas USA